## Day 1. (Monday 12th)  11.00 hrs Registration and Official Welcome

### I. Ocular Disease & Treatment

**Chair:** Prof Alan Bird UCL

**11.30 - 13.15 hrs**

- **Prof Andrew Lotery.** Professor of Ophthalmology, University of Southampton. Lead of Clinical Trials Group (commercial and NHS funded). Principal Investigator on different charity funded research. Southampton, UK. “What patients want”
- **Dr Paul Kenna.** Research Ophthalmologist. The Research Foundation, The Royal Victoria Eye and Ear Hospital Dublin and The Ocular Genetics Unit, Trinity College Dublin (Ireland). “Autosomal Dominant Retinitis Pigmentosa”
- **Dr David Kent.** Consultant Ophthalmologist. The Vision Clinic, Kilkenny (Ireland). “Inflammation and the Retina: is it always bad?”
- **Prof Alan Bird.** Honorary Consultant Ophthalmologist at the Moorfields Eye Hospital; Emeritus Professor, Institute Of Ophthalmology, University College London (UK). “Selection of early AMD patients for clinical trials: more than one disease”

### LUNCH

### II. Ocular Drug Discovery

**Chair:** Dr Breandan N. Kennedy UCD

**14.00 - 16.00 hrs**

- **Dr Breandan Kennedy.** Senior Lecturer and Principal Investigator in UCD SBBS – Conway Institute, University College Dublin (Ireland). “Phenotype based discovery of novel drugs for blindness”
- **Dr Javier Terriente.** Chief Science Officer in Ze-Clinics, Barcelona (Spain). “ZeClinics. Drug discovery through zebrafish”
- **Dr Philipp Gribbon.** EU Opensecreen Project Coordinator. Leibniz-Institut für Molekulare Pharmakologie (FMP) im Forschungsverbund Berlin e.V., Germany.
- **Dr Robert Haigh.** Chief Operating Officer at KalVista, Porton Down (UK). "Plasma kallikrein as a target in diabetic macular edema"
- **Dr Alfonso Blanco.** Director of Conway Core Facilities, UCD SBBS – Conway Institute, University College Dublin (Ireland). “How can Cytomics help you in Drug Discovery?”

- **Talk selected from submitted abstracts**

### COFFEE BREAK / POSTER SESSION

### III. Ocular Drug Development & Delivery

**Chair:** Prof David Brayden UCD

**16.30 – 18.00 hrs**

- **Dr Thakur Raghu Raj Singh.** Lecturer in Pharmaceutics in the School of Pharmacy and PI in Advanced Polymeric Drug Delivery Systems, Queen's University Belfast (UK). “Minimally-Invasive and long-acting ocular drug delivery strategies”
- **Prof Clive G. Wilson.** E.F.A.P.S., F.C.R.S., J P Todd Professor of Pharmaceutics. Education Liaison & Senate, European Federation for Pharmaceutical Sciences. Strathclyde Institute of Pharmacy and Biomedical Sciences Glasgow, Scotland (UK). “Do we have the hand to win the game?”
- **Prof Abhay Pandit.** Professor of Biomedical Engineering at National University of Ireland, Galway (Ireland). “Understanding the host for designing drug delivery systems”
- **Dr Brian Fennell.** PI in Global Biotherapeutics Technologies, Pfizer. Dublin (Ireland). “Multi-parametric optimisation and characterisation of antibody binding domains for chronic dosing.”

- **Talk selected from submitted abstracts**

### IV. 3DNET Management/Advisory Boards Committee Meeting

**Chair:** Prof David Brayden UCD

**18.00 – 19.00 hrs**

**SOCIAL DINNER**
Day 2. (Tuesday 13th)

V. **Preclinical Models and Clinical Trials** *(Chaired by Prof Brendan Buckley ICON)*
   (9.30 – 10.45 hrs)
   - **Prof Brendan Buckley.** ICON Chief Medical Officer, Dublin (Ireland). “Bringing discoveries from the bench into man in a regulated world”
   - **Dr Cyril Clarke.** ICON Vice-President of Translational Medicine, Dublin (Ireland). “Current endpoints - opportunities or threats in the translational space?”
   - **Dr Rob Jones.** Co-founder of the SME and Diabetes Project Manager at the CRO RenaSci, Nottingham (UK). “Preclinical Models to study Obesity and Diabetes”
   - Talk selected from submitted abstracts

   **COFFEE BREAK/ POSTER SESSION**

VI. **H2020 Round Table and Open discussion** *(Conway Boardroom)*
   (11.15 – 12.00 hrs)

VII. **Plenary lecture / Conway Class Seminar**
    (12.00 - 13.00 hrs)
    **Prof Yihai Cao.** Professor at the Microbiology and Tumor Biology Center in Karolinska Institutet and founder of Clanotech, Stockholm (Sweden). “Targeting angiogenesis and fibrosis for treatment of eye disease”